{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:31:14Z","timestamp":1791963074190,"version":"4.3.4"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Pediatric Acute Lymphoblastic Leukemia (ALL) cure rates have improved exponentially over the past five decades with now over 90% of children achieving long-term survival. A direct contributor to this remarkable feat is the development and expanded understanding of combination chemotherapy. Asparaginase is the most recent addition to the ALL chemotherapy backbone and has now become a hallmark of therapy. It is generally accepted that the therapeutic effects of asparaginase is due to depletion of the essential amino acid asparagine, thus occupying a unique space within the therapeutic landscape of ALL. Pharmacokinetic and pharmacodynamic profiling have allowed a detailed and accessible insight into the biochemical effects of asparaginase resulting in regular clinical use of therapeutic drug monitoring (TDM). Asparaginase's derivation from bacteria, and in some cases conjugation with a polyethylene glycol (PEG) moiety, have contributed to a unique toxicity profile with hypersensitivity reactions being the most salient. Hypersensitivity, along with several other toxicities, has limited the use of asparaginase in some populations of ALL patients. Both TDM and toxicities have contributed to the variety of approaches to the incorporation of asparaginase into the treatment of ALL. Regardless of the approach to asparagine depletion, it has continually demonstrated to be among the most important components of ALL therapy. Despite regular use over the past 50 years, and its incorporation into the standard of care treatment for ALL, there remains much yet to be discovered and ample room for improvement within the utilization of asparaginase therapy.<\/jats:p>","DOI":"10.3389\/fped.2022.902117","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T01:31:07Z","timestamp":1656552667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":90,"title":["Current Use of Asparaginase in Acute Lymphoblastic Leukemia\/Lymphoblastic Lymphoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Luke","family":"Maese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1084\/jem.118.1.99","article-title":"Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects: I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance","volume":"118","author":"Broome","year":"1963","journal-title":"J Exp Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3109\/10428194.2010.537796","article-title":"Asparaginase revisited","volume":"52","author":"van den Berg","year":"2011","journal-title":"Leuk Lymphoma."},{"key":"B4","first-page":"101","article-title":"L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies from Children's Cancer Study Group","volume":"65","author":"Nesbit","year":"1981","journal-title":"Cancer Treat Rep."},{"key":"B5","first-page":"535","article-title":"L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia","volume":"37","author":"Ortega","year":"1977","journal-title":"Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0976-500X.184769","article-title":"L-asparaginase in the treatment of patients with acute lymphoblastic leukemia","volume":"7","author":"Egler","year":"2016","journal-title":"J Pharmacol Pharmacother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer","volume":"117","author":"Pieters","year":"2011"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"Inge","year":"2016","journal-title":"Haematologica."},{"key":"B10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12079-018-0492-0","article-title":"Protein PEGylation for cancer therapy: bench to bedside","volume":"13","author":"Gupta","year":"2019","journal-title":"J Cell Commun Signal."},{"key":"B11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0142-9612(00)00193-9","article-title":"Peptide and protein PEGylation: a review of problems and solutions","volume":"22","author":"Veronese","year":"2001","journal-title":"Biomaterials."},{"key":"B12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/978-1-4615-4811-9_69","article-title":"The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia","volume":"457","author":"Asselin","year":"1999","journal-title":"Adv Exp Med Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/pbc.25757","article-title":"Activity and toxicity of intravenous Erwinia asparaginase following allergy to e coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia","volume":"63","author":"Vrooman","year":"2016","journal-title":"Pediatric blood & cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/MPH.0b013e3181483df1","article-title":"Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study","volume":"29","author":"Wacker","year":"2007","journal-title":"J Pediatr Hematol Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/leu.2008.165","article-title":"Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study","volume":"22","author":"Appel","year":"2008","journal-title":"Leukemia."},{"key":"B16","first-page":"349","article-title":"Clinical pharmacology of polyethylene glycol-L-asparaginase","volume":"14","author":"Ho","year":"1986","journal-title":"Drug Metab Dispos."},{"key":"B17","volume-title":"Oncaspar (pegaspargase).","author":"Package","year":"1994"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","article-title":"An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia","volume":"75","author":"Ettinger","year":"1995","journal-title":"Cancer."},{"key":"B19","first-page":"213","article-title":"A Phase II study of polyethylene glycol (PEG) conjugated lasparaginase in patients with refractory acute leukemias","volume":"29","author":"Kurtzberg","year":"1988","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"Drug approval summary: pegaspargase (Oncaspar\u00ae) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.4070","article-title":"Abstracts of the 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, The Convention Centre Dublin, Dublin, Ireland August 25-28, 2016","volume":"25","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1182\/blood.V128.22.5155.5155","article-title":"Systematic literature review evidence of pegaspargase for treatment of acute lymphoblastic leukemia (ALL)","volume":"128","author":"Lebedinsky","year":"2016","journal-title":"Blood."},{"key":"B25","first-page":"244","article-title":"Efficacy and safety of PEG-asparaginase vs E. coli","volume-title":"Transl Pediatr.","author":"Dai","year":"2021"},{"key":"B26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13561-019-0257-3","article-title":"The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis","volume":"9","author":"Hu","year":"2019","journal-title":"Health Econ Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/1078-0432.CCR-19-1255","article-title":"FDA approval summary: calaspargase pegol-mknl for treatment of acute lymphoblastic leukemia in children and young adults","volume":"26","author":"Li","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1158\/1078-0432.CCR-19-2975","article-title":"Space for Calaspargase? A new asparaginase for acute lymphoblastic leukemia","volume":"26","author":"Lew","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B31","volume-title":"(Asparaginase Erwinia chrysanthemi) [package insert].","author":"ERWINAZE","year":"2019"},{"key":"B32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/1097-0142(197208)30:2<376::AID-CNCR2820300212>3.0.CO","article-title":"Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer","volume":"30","author":"Ohnuma","year":"1972"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/sj.leu.2403011","article-title":"Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients","volume":"17","author":"Wang","year":"2003","journal-title":"Leukemia."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/pbc.22225","article-title":"Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia","volume":"54","author":"Vrooman","year":"2010","journal-title":"Pediatric Blood Cancer."},{"key":"B36","first-page":"507","volume-title":"Blood.","author":"Salzer","year":"2013"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e29169","DOI":"10.1002\/pbc.29169","article-title":"Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?","volume":"68","author":"Maese","year":"2021","journal-title":"Pediatr Blood Cancer."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2021-147023","article-title":"Initial results from a phase 2\/3 study of recombinant Erwinia asparaginase (JZP458) in patients with acute lymphoblastic leukemia (ALL)\/lymphoblastic lymphoma (LBL) who are allergic\/hypersensitive to E. coli-Derived Asparaginases","volume":"138","author":"Maese","year":"2021","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2141.2009.07923.x","article-title":"population pharmacokinetic model for pegylated-asparaginase in children","volume":"148","author":"Hempel","year":"2010","journal-title":"Br J Haematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s002800100286","article-title":"Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration","volume":"48","author":"Albertsen","year":"2001","journal-title":"Cancer Chemother Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1046\/j.1365-2141.2001.03148.x","article-title":"Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system","volume":"115","author":"Albertsen","year":"2001","journal-title":"Br J Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3324\/haematol.2016.149195","article-title":"Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients","volume":"102","author":"Sassen","year":"2017","journal-title":"Haematologica."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1200\/JCO.18.02439","article-title":"Antibodies predict pegaspargase allergic reactions and failure of rechallenge","volume":"37","author":"Liu","year":"2019","journal-title":"J Clin Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/bjh.16254","article-title":"Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker","volume":"189","author":"Kloos","year":"2020","journal-title":"Br J Haematol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3324\/haematol.2020.258525","article-title":"Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia","volume":"107","author":"Khalil","year":"2022","journal-title":"Haematologica."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/leu.2012.102","article-title":"Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia","volume":"26","author":"Liu","year":"2012","journal-title":"Leukemia."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3324\/haematol.2018.199448","article-title":"Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors Fc\u03b5RI and Fc\u03b3RIII","volume":"104","author":"Rathod","year":"2019","journal-title":"Haematologica."},{"key":"B49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/10428194.2016.1213826","article-title":"Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia","volume":"58","author":"Burke","year":"2017","journal-title":"Leuk Lymphoma."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/pbc.24938","article-title":"Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial","volume":"61","author":"Plourde","year":"2014","journal-title":"Pediatr Blood Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/1097-0142(19920701)70:1<201::AID-CNCR2820700131>3.0.CO;2-M","article-title":"Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase","volume":"70","author":"Billett","year":"1992","journal-title":"Cancer."},{"key":"B52","article-title":"Incidence of hypersensitivity reactions (HSR) reactions (HSR) to peg-asparaginase (PEG-ASP) in 6136 patients treated in the AIEOP-BFM ALL 2009 study protocol","volume-title":"Blood.","author":"Rizzari","year":"2019"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1080\/10428194.2017.1397658","article-title":"Severe pegaspargase hypersensitivity reaction rates (grade \u22653) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials","volume":"59","author":"Burke","year":"2018","journal-title":"Leukemia Lymphoma."},{"key":"B54","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2021.11.016","article-title":"Hypersensitivity to Pegylated Ecoli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group","volume":"162","author":"Brigitha","year":"2022","journal-title":"Eur J Cancer."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e29051","DOI":"10.1002\/pbc.29051","article-title":"Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with acute lymphoblastic leukemia","volume":"68","author":"McCormick","year":"2021","journal-title":"Pediatr Blood Cancer."},{"key":"B56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-143248","article-title":"Premedication and longer infusion time do not reduce the incidence of hypersensitivity reactions to pegaspargase","volume":"136","author":"Hughes","year":"2020","journal-title":"Blood."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e27797","DOI":"10.1002\/pbc.27797","article-title":"Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions","volume":"66","author":"Cooper","year":"2019","journal-title":"Pediatr Blood Cancer."},{"key":"B58","unstructured":"The impact of pegasparagase premedication on hypersensitivity reactions in pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) patients\n            MenigS\n            AJ\n            TuckerS.\n          Presented at HOPA 16th Annual Conference2020"},{"key":"B59","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/bjh.15660","article-title":"Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008","volume":"184","author":"H\u00f8jfeldt","year":"2019","journal-title":"Br J Haematol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/blood-2015-02-628800","article-title":"Genome-wide analysis links NFATC2 with asparaginase hypersensitivity","volume":"126","author":"Fernandez","year":"2015","journal-title":"Blood."},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000977","article-title":"Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion","volume-title":"ESMO Open.","author":"Baruchel","year":"2020"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e28021","DOI":"10.1002\/pbc.28021","article-title":"Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"67","author":"August","year":"2020","journal-title":"Pediatr Blood Cancer."},{"key":"B64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019003407","article-title":"Predicting success of desensitization after pegaspargase allergy","volume":"135","author":"Swanson","year":"2020","journal-title":"Blood."},{"key":"B65","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/08880018.2019.1634778","article-title":"PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability Pediatric hematology and oncology","volume":"36","author":"Verma","year":"2019"},{"key":"B66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2020-138840","article-title":"Pegaspargase re-challenge after grade 2 hypersensitivity reaction in childhood acute lymphoblastic leukemia: results from DFCI 16-001","volume":"136","author":"Vrooman","year":"2020","journal-title":"Blood."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","article-title":"Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study","volume":"18","author":"Wolthers","year":"2017","journal-title":"Lancet Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"20150423","DOI":"10.1098\/rstb.2015.0423","article-title":"Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2","volume":"371","author":"Peng","year":"2016","journal-title":"Philos Trans Royal Soc B."},{"key":"B69","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjh.12016","article-title":"Asparaginase-associated pancreatitis in children","volume":"159","author":"Raja","year":"2012","journal-title":"Br J Haematol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age","volume":"38","author":"Rank","year":"2020","journal-title":"J Clin Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1200\/JCO.2015.64.5812","article-title":"Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia","volume":"34","author":"Liu","year":"2016","journal-title":"Proc Am Assoc Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/leu.2016.203","article-title":"Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol","volume":"31","author":"Wolthers","year":"2017","journal-title":"Leukemia."},{"key":"B73","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0145-2126(00)00017-5","article-title":"Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia","volume":"24","author":"Bushman","year":"2000","journal-title":"Leuk Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/leu.2012.290","article-title":"The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia","volume":"27","author":"Truelove","year":"2013","journal-title":"Leukemia."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood."},{"key":"B76","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br J Haematol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/rth2.12182","article-title":"Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: risk factors and effect on prognosis","volume":"3","author":"Klaassen","year":"2019","journal-title":"Res Pract Thromb Haemost."},{"key":"B78","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12887-017-0877-x","article-title":"TropicALL study: thromboprophylaxis in children treated for acute lymphoblastic leukemia with low-molecular-weight heparin: a multicenter randomized controlled trial","volume":"17","author":"Klaassen","year":"2017","journal-title":"BMC Pediatr."},{"key":"B79","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1055\/s-0039-1679938","article-title":"PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)-rationale and design","volume":"119","author":"O'Brien","year":"2019","journal-title":"Thromb Haemost."},{"key":"B80","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/jth.13895","article-title":"The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH","volume":"16","author":"Tullius","year":"2018","journal-title":"J Thrombosis Haemostasis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/tpj.2016.7","article-title":"Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia","volume":"17","author":"Alachkar","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"B82","article-title":"Asparaginase induced liver enzyme elevation is more prevalent in hispanics children with ALL and in patients with SOD2 rs4880 CC genotype","volume-title":"Blood.","author":"Wu","year":"2021"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e28063","DOI":"10.1002\/pbc.28063","article-title":"Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia","volume":"67","author":"Hashmi","year":"2020","journal-title":"Pediatr Blood Cancer."},{"key":"B84","doi-asserted-by":"publisher","first-page":"26891","DOI":"10.1002\/pbc.26891","article-title":"Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens","volume":"65","author":"Denton","year":"2018","journal-title":"Pediatric Blood Cancer."},{"key":"B85","doi-asserted-by":"publisher","first-page":"7551","DOI":"10.1002\/cam4.4281","article-title":"Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia","volume":"10","author":"Schulte","year":"2021","journal-title":"Cancer Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/8904_2012_156","article-title":"High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase","volume":"7","author":"Heitink-Poll\u00e9","year":"2013","journal-title":"JIMD Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","article-title":"The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia","volume":"99","author":"Tong","year":"2014","journal-title":"Haematologica."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.ejca.2014.06.023","article-title":"Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia","volume":"50","author":"Bhojwani","year":"2014","journal-title":"Eur J Cancer."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2010-10-311969","article-title":"Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia","volume":"117","author":"Kawedia","year":"2011","journal-title":"Blood."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3324\/haematol.2020.257550","article-title":"Effect of post-consolidation regimen on symptomatic osteonecrosis in three DCOG acute lymphoblastic leukemia protocols","volume":"106","author":"van Atteveld","year":"2021","journal-title":"Haematologica."},{"key":"B91","doi-asserted-by":"publisher","first-page":"26555","DOI":"10.1002\/pbc.26555","article-title":"Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU","volume":"64","author":"Lebovic","year":"2017","journal-title":"Pediatric Blood Cancer."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1182\/blood-2014-11-551481","article-title":"How I treat acute lymphoblastic leukemia in older adolescents and young adults","volume":"125","author":"Curran","year":"2015","journal-title":"Blood."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.20.00494","article-title":"Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from children's oncology group AALL0932","volume":"39","author":"Angiolillo","year":"2021","journal-title":"J Clin Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1182\/blood.V124.21.793.793","article-title":"Outstanding outcome for children with standard risk-low (SR-Low) acute lymphoblastic leukemia (ALL) and no benefit to intensified peg-asparaginase (PEG-ASNase) therapy: results of children's oncology group (COG) study AALL0331","volume":"124","author":"Mattano","year":"2014","journal-title":"Blood."},{"key":"B95","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/s-2008-1034450","article-title":"The BFM 76\/79 acute lymphoblastic leukemia therapy study (author's transl)","volume":"193","author":"Henze","year":"1981","journal-title":"Klin Padiatr."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2021.04.006","article-title":"Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: a population-based study in Ontario, Canada","volume":"151","author":"Gupta","year":"2021","journal-title":"Eur J Cancer."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO.18.01877","article-title":"Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study","volume":"37","author":"Albertsen","year":"2019","journal-title":"J Clin Oncol."},{"key":"B101","first-page":"6568","article-title":"Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor","volume":"51","author":"Asselin","year":"1991","journal-title":"Cancer Res."},{"key":"B102","first-page":"4554","article-title":"L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"Riccardi","year":"1981","journal-title":"Cancer Res."},{"key":"B103","first-page":"107","article-title":"Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961)","volume":"18","author":"Grigoryan","year":"2004","journal-title":"In vivo."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","author":"Boos","year":"1996","journal-title":"Eur J Cancer."},{"key":"B105","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/BF00686177","article-title":"Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey","volume":"32","author":"Berg","year":"1993","journal-title":"Cancer Chemother Pharmacol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3324\/haematol.2018.206433","article-title":"Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study","volume":"104","author":"Rizzari","year":"2019","journal-title":"Haematologica."},{"key":"B108","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00280-021-04315-0","article-title":"Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase","volume":"88","author":"Panetta","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/A:1008368916800","article-title":"L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving im or iv Erwinia C or E coli L-asparaginase as first exposure","volume":"11","author":"Rizzari","year":"2000","journal-title":"Ann Oncol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1182\/blood-2008-04-149443","article-title":"Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial","volume":"112","author":"Pieters","year":"2008","journal-title":"Blood."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1080\/10428194.2018.1542146","article-title":"Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4()","volume":"60","author":"Schore","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"B112","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/pbc.25369","article-title":"Myocardial iron load and fibrosis in long term survivors of childhood leukemia","volume":"62","author":"Cheung","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"B113","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1078155214551590","article-title":"Hyperammonemia secondary to asparaginase: a case series","volume":"22","author":"Nussbaum","year":"2016","journal-title":"J Oncol Pharm Pract."},{"key":"B114","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL","volume":"28","author":"M\u00fcller","year":"1998","journal-title":"Crit Rev Oncol Hematol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/pbc.25299","article-title":"Clinical application of asparaginase activity levels following treatment with pegaspargase","volume":"62","author":"Bleyer","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","article-title":"Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2013Dana-Farber Cancer Institute ALL Consortium Protocol 00-01","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1080\/10428194.2019.1608530","article-title":"A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage","volume":"60","author":"Marini","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"B118","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized asparaginase dosing in childhood acute lymphoblastic leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J Clin Oncol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"26873","DOI":"10.1002\/pbc.26873","article-title":"Outcome of pediatric patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children's Oncology Group","volume":"65","author":"Rau","year":"2018","journal-title":"Pediatric Blood Cancer."},{"key":"B120","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1107\/S2053230X20008328","article-title":"Proline\/alanine-rich sequence (PAS) polypeptides as an alternative to PEG precipitants for protein crystallization","volume":"76","author":"Schiefner","year":"2020","journal-title":"Acta Crystallogr F Struct Biol Commun."},{"key":"B121","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cocis.2017.06.004","article-title":"PASylation\u00ae: a versatile technology to extend drug delivery","volume":"31","author":"Binder","year":"2017","journal-title":"Curr Opin Colloid Interface Sci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"10124","DOI":"10.3390\/ijms22010124","article-title":"PASylated thymosin \u03b11: a long-acting immunostimulatory peptide for applications in oncology and virology","volume":"22","author":"Binder","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1900385","DOI":"10.1002\/biot.201900385","article-title":"PASylation enhances the stability, potency, and plasma half-life of interferon \u03b1-2a: a molecular dynamics simulation","volume":"15","author":"Shamloo","year":"2020","journal-title":"Biotechnol J."},{"key":"B124","doi-asserted-by":"publisher","first-page":"627","DOI":"10.31557\/APJCP.2021.22.2.627","article-title":"The effective control of hyperuricemia in cancer patients: a new recombinant conjugated variant of urate oxidase","volume":"22","author":"Najjari","year":"2021","journal-title":"Asian Pac J Cancer Prev."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/MPA.0000000000000394","article-title":"Asparagine synthetase expression and phase I study with L-asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma","volume":"44","author":"Bachet","year":"2015","journal-title":"Pancreas."},{"key":"B126","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2019.10.020","article-title":"Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized Phase IIb trial","volume":"124","author":"Hammel","year":"2020","journal-title":"Eur J Cancer."},{"key":"B127","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ajh.24093","article-title":"A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRASPALL\/GRAALL-SA2-2008 study","volume":"90","author":"Hunault-Berger","year":"2015","journal-title":"Am J Hematol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2141.2011.08588.x","article-title":"L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial","volume":"153","author":"Domenech","year":"2011","journal-title":"Br J Haematol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2020-139373","article-title":"NOR-GRASPALL2016 (NCT03267030): asparaginase encapsulated in erythrocytes (eryaspase)-a promising alternative to peg-asparaginase in case of hypersensitivity","volume":"136","author":"Lynggaard","year":"2020","journal-title":"Blood."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.902117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T01:31:19Z","timestamp":1656552679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.902117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":129,"alternative-id":["10.3389\/fped.2022.902117"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.902117","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"article-number":"902117"}}